COVID-19 trials registries data warehouse

http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48939

Dr Pranav Sharma

nareshpalsingh@gmail.com

2020-11-12

Not recruiting

RCT

Randomized

Parallel

Blind label

single-center

Treatment

1. Patients infected with SARS-CoV-2 on the day one of admission before administration of any routine treatment. <br/ > <br/ >2. Patientsâ?? age should be 18 years and above at the time of enrollment, considering he/she can provide informed legal consent. <br/ > <br/ >3. Patients presented with mild to moderate COVID-19 illness. <br/ > <br/ >4. Patients presented to the hospital within 10 days of symptom onset.

1. Patients infected with SARS-CoV-2 admitted in the hospital for more than one day and on routine treatment for COVID-19. <br/ > <br/ >2. Any patient who has severe illness debilitating the patient to provide consent as well as adopt the study procedure. <br/ > <br/ >3. Patients less than 18 years of age at the time of enrollment. <br/ > <br/ >4. Patients already using oral/intra-nasal antiseptic. <br/ > <br/ >5. Any patient with known thyroid disorders. <br/ > <br/ >6. Pregnant and lactating women. <br/ > <br/ >7. Patients who disagree to consent. <br/ >

2

Uttar Pradesh University Of Medical Sciences

18

99

India

Mild/moderate disease at enrollment

2: Mild/moderate disease at enrollment

32

To estimate the change in the viral load and Ct value in the oropharyngeal/nasopharyngeal samples of the patients infected with SARS-CoV-2.Timepoint: 5 minutes; 3 hours and 6 hours of administration of interventional agents

| Declared number of arm (2.0) differs from found arms (3.0)

Phase 3

[{"arm_notes": "", "treatment_id": 1015, "treatment_name": "Povidone-iodine", "treatment_type": "Mouthwash", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]